Optic Nerve and Retinal Functions With Bevacizumab
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01361828|
Recruitment Status : Completed
First Posted : May 27, 2011
Last Update Posted : May 27, 2011
|Condition or disease||Intervention/treatment|
|Choroidal Neovascular Membrane||Procedure: Electrophysiology|
|Study Type :||Observational|
|Actual Enrollment :||45 participants|
|Official Title:||Electrophysiological Assessment of Optic Nerve and Retinal Functions Following Intravitreal Injection of Bevacizumab (Avastin).|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||July 2010|
|Actual Study Completion Date :||July 2010|
Patients with choroidal neovascularization
CNV due to Age-Related Macular Degenerations and Myopia were included.
Visual Evoked Potential and Elctroretinogram
- Visual Evoked Potential and Electroretinogram [ Time Frame: 4 weeks ]VEP and ERG baseline and at 1 and 4 weeks post intravitreal injection of bevacizumab.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01361828
|Cairo, --- Select One ---, Egypt, 11421|
|Principal Investigator:||Tamer A macky||Cairo University|